Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Colorcon
McKinsey
Medtronic
Boehringer Ingelheim

Last Updated: November 27, 2022

CLINICAL TRIALS PROFILE FOR TENORMIN


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Tenormin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00133692 ↗ INVEST: INternational VErapamil SR Trandolapril STudy Completed Abbott Phase 4 1997-09-01 Because blood pressure affects the heart, blood vessels, kidneys, and the entire body, it is important to keep it as normal as possible. There are several different ways to control blood pressure and to prevent or limit the development of heart disease due to high blood pressure. The purpose of this study is to compare two treatments to see how well they work and the difference in their side effects. One treatment includes the use of a calcium antagonist drug (Isoptin sustained release [SR] or Verapamil SR). The other treatment excludes the calcium antagonist and may include a non-calcium antagonist drug called a beta blocker (Tenormin or Atenolol). Both treatments may also include medication called angiotensin converting enzyme (ACE) inhibitors and water pills. None of the drugs in this study are experimental, they are all approved by the Food and Drug Administration (FDA).
NCT00133692 ↗ INVEST: INternational VErapamil SR Trandolapril STudy Completed University of Florida Phase 4 1997-09-01 Because blood pressure affects the heart, blood vessels, kidneys, and the entire body, it is important to keep it as normal as possible. There are several different ways to control blood pressure and to prevent or limit the development of heart disease due to high blood pressure. The purpose of this study is to compare two treatments to see how well they work and the difference in their side effects. One treatment includes the use of a calcium antagonist drug (Isoptin sustained release [SR] or Verapamil SR). The other treatment excludes the calcium antagonist and may include a non-calcium antagonist drug called a beta blocker (Tenormin or Atenolol). Both treatments may also include medication called angiotensin converting enzyme (ACE) inhibitors and water pills. None of the drugs in this study are experimental, they are all approved by the Food and Drug Administration (FDA).
NCT00389168 ↗ Irbesartan and Atenolol in Hypertensive Heart Disease Completed Bristol-Myers Squibb Phase 2/Phase 3 1995-04-01 The renin-angiotensin-aldosterone system has been implicated in the control of structural changes of the heart and the vasculature, beyond the effects on blood pressure. This projects examines the importance of the renin-angiotensin-aldosterone system and the sympathetic nervous system in the control of cardiac and vascular structure and function in subjects with hypertension.Patients with hypertension and left ventricular hypertrophy were randomized to an angiotensin receptor blocker or a beta adrenergic receptor blocker for 48 weeks. Repeat investigations of blood pressure, structure and function of the heart and the vascular tree, and neurohormones were performed. Two control groups, consisting of normotensive subjects and of hypertensive subjects with no cardiac hypertrophy were also examined for comparison.
NCT00389168 ↗ Irbesartan and Atenolol in Hypertensive Heart Disease Completed Sanofi Phase 2/Phase 3 1995-04-01 The renin-angiotensin-aldosterone system has been implicated in the control of structural changes of the heart and the vasculature, beyond the effects on blood pressure. This projects examines the importance of the renin-angiotensin-aldosterone system and the sympathetic nervous system in the control of cardiac and vascular structure and function in subjects with hypertension.Patients with hypertension and left ventricular hypertrophy were randomized to an angiotensin receptor blocker or a beta adrenergic receptor blocker for 48 weeks. Repeat investigations of blood pressure, structure and function of the heart and the vascular tree, and neurohormones were performed. Two control groups, consisting of normotensive subjects and of hypertensive subjects with no cardiac hypertrophy were also examined for comparison.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Tenormin

Condition Name

Condition Name for Tenormin
Intervention Trials
Hypertension 3
Preeclampsia 2
Healthy 2
Marfan Syndrome 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Tenormin
Intervention Trials
Hypertension 3
Pre-Eclampsia 2
Arachnodactyly 2
Atrial Fibrillation 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Tenormin

Trials by Country

Trials by Country for Tenormin
Location Trials
United States 26
Korea, Republic of 1
Canada 1
Sweden 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Tenormin
Location Trials
Minnesota 3
Tennessee 3
Massachusetts 2
Florida 2
Georgia 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Tenormin

Clinical Trial Phase

Clinical Trial Phase for Tenormin
Clinical Trial Phase Trials
Phase 4 5
Phase 3 3
Phase 2/Phase 3 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Tenormin
Clinical Trial Phase Trials
Completed 9
Unknown status 4
Terminated 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Tenormin

Sponsor Name

Sponsor Name for Tenormin
Sponsor Trials
Emory University 2
Mayo Clinic 2
University of Florida 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Tenormin
Sponsor Trials
Other 21
Industry 12
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Medtronic
McKesson
Mallinckrodt
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.